- |||||||||| zanidatamab (ZW25) / Jazz
Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer (BC) (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_393; Background Outcome of patients (pts) w/ stage I node neg HER2+ treated w/ wkly paclitaxel x 12 doses and trastuzumab x 1yr is excellent (10yr RFS 96%)...Three received tamoxifen and 3 letrozole...Conclusions Neoadjuvant zanidatamab for 3 months showed significant efficacy, (pCR/RCB-1 64%) w/ acceptable safety profile in pts w/ stage I node neg HER2+ BC. The trial is ongoing and has been modified to increase treatment duration to 5mths (10 cycles).
- |||||||||| metformin / Generic mfg., letrozole / Generic mfg., spironolactone / Generic mfg.
Journal: Polycystic Ovary Syndrome: Common Questions and Answers. (Pubmed Central) - Mar 20, 2023 Metformin added to lifestyle management is first-line therapy for patients with metabolic complications such as insulin resistance. Patients with PCOS are at increased risk of depression and obstructive sleep apnea, and screening is recommended.
- |||||||||| Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date, Metastases: ABIGAIL: ABemaciclib, ET (clinicaltrials.gov) - Mar 16, 2023 P2, N=160, Recruiting, This study provides new insights into the application of immunotherapy for HR+ BCs, especially those who respond to endocrine therapy. Trial primary completion date: Feb 2023 --> Sep 2023
- |||||||||| nitroprusside / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal: The regulatory effect of sex steroids on the RhoA/ROCK pathway in the rat distal vagina. (Pubmed Central) - Mar 14, 2023 Letrozole combined with ethinylestradiol and cyproterone acetate tablets can enhance the treatment efficiency of PCOS and improve serum sex hormones and lipid metabolism in PCOS patients. Androgens, by inhibiting the RhoA/ROCK pathway, could positively contribute to vaginal smooth muscle relaxation, favoring sexual intercourse.
- |||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Which are the clinicopathological characteristics useful to define the metastatic breast cancer patients that will respond to CDK4/6 inhibitors and hormone therapy? An Italian real-world experience (Section 37; Poster Board #18) - Mar 14, 2023 - Abstract #AACR2023AACR_6923; 177 mBC patients 66 of whom were treated with CD4/6 inhibitors plus letrozole and 111 treated with CDK4/6 inhibitors and fulvestrant were enrolled in the study...Finally, the neutropenia status was associated with a more than double risk of progression/death with respect to patients without neutropenia (HR=2.311; p=0.025). Given that we identified a set of factors associated with the probability to develop neutropenia and considering that neutropenia itself is associated with an increased risk of progression, these baseline characteristics should be taken into account in order to reduce the occurrence of both neutropenia and disease progression.
- |||||||||| Kisqali (ribociclib) / Novartis
Cancer cell communication with macrophages prevents T cell activation during emergence of cell cycle therapy resistance (Section 33; Poster Board #16) - Mar 14, 2023 - Abstract #AACR2023AACR_5763; These results indicate that cancer communications promoting an immune-cold TME predispose tumors to develop CDK4/6 cell cycle inhibitor resistance, and that the beneficial effects of blocking cancer cell proliferation must be balanced against their inhibitory effect on immune cell division and activation. An optimal treatment strategy will require coupling the prevention of cancer division with activation of an effective cytotoxic T-cell response.
- |||||||||| letrozole / Generic mfg.
Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy (Room W311 E-H - Convention Center) - Mar 14, 2023 - Abstract #AACR2023AACR_5553; We investigated the tumor microenvironment (TME) in estrogen receptor positive (ER+) primary breast cancers from stage I-III patients treated with estrogen deprivation (ED, induced with letrozole) for 10-21 days...In summary, our study shows that activated anti-tumor immune cells are enriched in the TME of ER+ breast tumors resistant to estrogen deprivation, whereas ED-sensitive tumors show a more immunosuppressed or immune cold milieu. These data suggest a potential causal link between antiestrogen treatment and modulation of antitumor immunity in ER+ breast cancers.
- |||||||||| Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Journal, HEOR, Combination therapy, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2. (Pubmed Central) - Mar 13, 2023 P3 This analysis with updated data assessed the cost-effectiveness of ribociclib versus palbociclib, both in combination with letrozole, in the setting of 1L therapy of postmenopausal women with HR+/HER2- ABC, from a United Kingdom (UK) National Health Service perspective. At a
- |||||||||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Trial primary completion date, Combination therapy, Metastases: GOG-3039: Abemaciclib and Letrozole to Treat Endometrial Cancer (clinicaltrials.gov) - Mar 13, 2023 P2, N=50, Recruiting, At a Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2023 --> Dec 2023
- |||||||||| Journal, Metastases: Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients. (Pubmed Central) - Mar 10, 2023
Moreover, the expression of miR-199a and miR-663b was significantly correlated with the response to treatment, in which the expression of miR-199a was higher in the poor-response group (P=0.049), while the higher expression of miR-663b was seen in the good-response group (P=0.009). These findings state that the high plasma level of miR-199a and the low plasma level of miR-663b may be related to chemoresistance in patients with metastatic breast cancer.
- |||||||||| letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Enrollment change, Trial completion date: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov) - Mar 10, 2023 P3, N=5083, Active, not recruiting, These findings state that the high plasma level of miR-199a and the low plasma level of miR-663b may be related to chemoresistance in patients with metastatic breast cancer. N=10000 --> 5083 | Trial completion date: Feb 2023 --> Mar 2024
- |||||||||| tagtociclib (PF-07104091) / Pfizer
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: PF-07104091 as a Single Agent and in Combination Therapy (clinicaltrials.gov) - Mar 10, 2023 P1/2, N=320, Recruiting, N=10000 --> 5083 | Trial completion date: Feb 2023 --> Mar 2024 Phase classification: P2 --> P1/2 | N=240 --> 320 | Trial completion date: Nov 2027 --> Jan 2026 | Trial primary completion date: Nov 2026 --> Jan 2025
- |||||||||| Biomarker, Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Biomarker-driven therapy in endometrial cancer. (Pubmed Central) - Mar 7, 2023
Other treatment regimens being evaluated in NSMP/CNL are hormonal combinations with cyclin-dependent kinase 4/6 inhibitors and letrozole...Treatment de-escalation is being evaluated in POLEmut cases given its favorable prognosis with or without adjuvant therapy. Molecular subtyping has important prognostic and therapeutic implications, and should guide patient management and clinical trial design in endometrial cancer, which is a molecularly driven disease.
- |||||||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: PLEASURABLE: Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (clinicaltrials.gov) - Mar 7, 2023 P1/2, N=59, Active, not recruiting, Trial primary completion date: Sep 2022 --> Sep 2023 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2020 --> Jun 2023
- |||||||||| Orserdu (elacestrant) / Menarini
Journal, Metastases: Elacestrant (Orserdu) for advanced or metastatic breast cancer. (Pubmed Central) - Mar 7, 2023 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2020 --> Jun 2023 No abstract available
|